Ran F - Search Results

1

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.

Qian J, Xu Z, Zhu P, Meng C, Liu Y, Shan W, He A, Gu Y, Ran F, Zhang Y, Ling Y. Qian J, et al. Among authors: ran f. J Nat Prod. 2021 Dec 24;84(12):3161-3168. doi: 10.1021/acs.jnatprod.1c00618. Epub 2021 Nov 21. J Nat Prod. 2021. PMID: 34806369

2

Overview of piperlongumine analogues and their therapeutic potential.

Zhu P, Qian J, Xu Z, Meng C, Zhu W, Ran F, Zhang W, Zhang Y, Ling Y. Zhu P, et al. Among authors: ran f. Eur J Med Chem. 2021 Aug 5;220:113471. doi: 10.1016/j.ejmech.2021.113471. Epub 2021 Apr 21. Eur J Med Chem. 2021. PMID: 33930801 Review.

3

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, Zhao G, Ling Y. Ran F, et al. Eur J Med Chem. 2022 Feb 5;229:114009. doi: 10.1016/j.ejmech.2021.114009. Epub 2021 Nov 22. Eur J Med Chem. 2022. PMID: 34839996 Review.

4

Recent development of BTK-based dual inhibitors in the treatment of cancers.

Ran F, Liu Y, Xu Z, Meng C, Yang D, Qian J, Deng X, Zhang Y, Ling Y. Ran F, et al. Eur J Med Chem. 2022 Apr 5;233:114232. doi: 10.1016/j.ejmech.2022.114232. Epub 2022 Feb 25. Eur J Med Chem. 2022. PMID: 35247756 Review.

5

TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.

Xu Z, Qian J, Meng C, Liu Y, Ding Q, Wu H, Li P, Ran F, Liu GQ, Wang Y, Ling Y. Xu Z, et al. Among authors: ran f. Theranostics. 2022 Feb 28;12(6):2535-2548. doi: 10.7150/thno.68074. eCollection 2022. Theranostics. 2022. PMID: 35401826 Free PMC article.

6

Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy.

Qian J, Xu Z, Meng C, Liu Y, Wu H, Wang Y, Yang J, Zheng H, Ran F, Liu GQ, Ling Y. Qian J, et al. Among authors: ran f. J Med Chem. 2022 Aug 11;65(15):10393-10407. doi: 10.1021/acs.jmedchem.2c00130. Epub 2022 Jul 25. J Med Chem. 2022. PMID: 35877176

7

Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects.

Ran F, Xie X, Wu Q, Wu H, Liu Y, Tao W, Sun Y, Wang R, Zhang Y, Ling Y. Ran F, et al. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114913. doi: 10.1016/j.ejmech.2022.114913. Epub 2022 Nov 10. Eur J Med Chem. 2023. PMID: 36399923

8

Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.

Ran F, Liu Y, Zhu J, Deng X, Wu H, Tao W, Xie X, Hu Y, Zhang Y, Ling Y. Ran F, et al. Bioorg Chem. 2023 May;134:106479. doi: 10.1016/j.bioorg.2023.106479. Epub 2023 Mar 13. Bioorg Chem. 2023. PMID: 36989958

9

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.

Ran F, Liu Y, Chen X, Zhuo H, Xu C, Li Y, Duan X, Zhao G. Ran F, et al. Bioorg Chem. 2021 Jul;112:104968. doi: 10.1016/j.bioorg.2021.104968. Epub 2021 May 7. Bioorg Chem. 2021. PMID: 34000704

10

Recent Developments in Androgen Receptor Antagonists.

Ran F, Xing H, Liu Y, Zhang D, Li P, Zhao G. Ran F, et al. Arch Pharm (Weinheim). 2015 Nov;348(11):757-775. doi: 10.1002/ardp.201500187. Epub 2015 Oct 13. Arch Pharm (Weinheim). 2015. PMID: 26462013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters